Press Release

James C. Stansel is new Executive V.P. & General Counsel

PhRMA July 12, 2016

Washington, DC (July 12, 2016) – The Pharmaceutical Research and Manufacturers of America (PhRMA) today announced James C. Stansel will join the organization as executive vice president and general counsel. He will oversee the organization’s legal department beginning August 1, 2016.

A former acting general counsel for the U.S. Department of Health and Human Services (HHS), Stansel served as the chief legal officer for the agency, as well as sub-agencies, including the U.S. Food and Drug Administration, the Centers for Medicare & Medicaid Services, the Centers for Disease Control and Prevention, the Health Resources and Services Administration and the National Institutes of Health. At HHS, Stansel also served as deputy general counsel and counselor to the secretary, advising on a wide range of health policy issues.

“With his deep legal expertise in complex health policy and regulatory issues, I am pleased to welcome Jim to the helm of our legal team,” said Stephen J. Ubl, president and CEO of PhRMA. “As our members push forward into new and exciting areas of research and development, Jim’s experience working with industry and government will enable him to provide valuable counsel and guidance to our industry.”

Stansel joins PhRMA from Sidley Austin LLP, where he is co-head of the global life sciences team and partner in the health care, government strategies and food and drug groups. He has represented clients in a variety of policy, regulatory and administrative matters, including Medicare and Medicaid coverage, coding and reimbursement, as well as in complex civil, criminal, appellate and administrative enforcement actions. Stansel has been recognized since 2011 in The Best Lawyers in America in both biotechnology law and health care law. He is also a member of Law360’s 2016 Life Sciences Editorial Advisory Board.

“The biopharmaceutical industry’s focus on saving, improving and sustaining lives through new treatments and cures is the backbone of today’s health care system,” said Stansel. “I am excited to join PhRMA and its impressive legal team to support the industry as it continues to lead in and redefine innovation.”

Stansel holds a J.D. from Yale Law School and a Bachelor of Science in economics from Brigham Young University.


About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier and more productive lives. Since 2000, PhRMA member companies have invested more than half a trillion dollars in the search for new treatments and cures, including an estimated $58.8 billion in 2015 alone.

Connect with PhRMA
For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.FromHopetoCures.org
www.Facebook.com/PhRMA
www.Twitter.com/PhRMA